Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
OTC:IDXG
Price:
1.55 USD
4.73%
Market Closed
Updated:
May 29, 2024
Interpace Biosciences Inc
Total Liabilities & Equity
|
Interpace Biosciences Inc
Total Liabilities & Equity Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Interpace Biosciences Inc
OTC:IDXG
|
Total Liabilities & Equity
$12.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-15%
|
|
|
DaVita Inc
NYSE:DVA
|
Total Liabilities & Equity
$17.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Total Liabilities & Equity
$14B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
CVS Health Corp
NYSE:CVS
|
Total Liabilities & Equity
$249.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
13%
|
|
|
Cigna Corp
NYSE:CI
|
Total Liabilities & Equity
$153.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Total Liabilities & Equity
$16.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
See Also
What is Interpace Biosciences Inc's Total Liabilities & Equity?
Total Liabilities & Equity
12.1m
USD
12.1m
USD
Based on the financial report for Mar 31, 2024, Interpace Biosciences Inc's Total Liabilities & Equity amounts to 12.1m USD.
What is Interpace Biosciences Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-15%
-15%
Over the last year, the Total Liabilities & Equity growth was -24%. The average annual Total Liabilities & Equity growth rates for Interpace Biosciences Inc have been -35% over the past three years , -26% over the past five years , and -15% over the past ten years .
You don't have any saved screeners yet
